In addition, the pilot in vivo xenograft data (Figure 6) using H460 lung cancer cells provide the proof of principle that targeting ERCC1-XPF can enhance cisplatin potency and also highlights NSC16168 as a potential lead structure for future drug development efforts towards targeting ERCC1-XPF. Here, ERCC1 is linked to lung cancer.